anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology.SUBSTANCE: microcapsule is proposed, containing probiotics and maintaining the activity thereof, and a method for production thereof. The microcapsule comprises probiotics. The first material of the microcapsule wall therein comprises casein, malt extract and xylooligosaccharide. The second material of the wall comprisesTremella fuciformispolysaccharide,Bletilla striatapolysaccharide,Atractylodes macrocephalapolysaccharide, guar gum and pectin in predetermined ratios. The method for producing a microcapsule involves centrifugation of a culture medium containing probiotic bacteria, removal of the supernatant, producing probiotic bacteria. Casein, malt extract, xylooligosaccharide and water are mixed in predetermined quantities, producing a mixed solution of the first material of the wall. The probiotic bacteria are therein added to the mixed solution of the first material of the wall and mixed producing a bacterial suspension. The produced bacterial suspension is slowly injected into a solution of gallic acid, settled for 5 to 20 minutes, the precipitate in the form of microgranules is collected, and the collected microgranules are washed in sterilised water.Tremella fuciformispolysaccharide,Bletilla striatapolysaccharide,Atractylodes macrocephalapolysaccharide, guar gum and pectin are added to water and mixed producing a mixed solution of the second material of the wall. The microgranules are introduced into the resulting solution and mixed producing a bacterial suspension. The bacterial suspension is then slowly injected into a solution of calcium lactate at a concentration of 0.05 to 0.5 mol/l, ensuring hardening, washed and filtered producing microcapsules, followed by freeze-drying thereof.EFFECT: makes it possible to reduce the negative impact of the environment on the activity of probiotics and to increase the quality of the probiotic preparation.9 cl, 3 dwg, 1 tbl, 6 ex
<P>PROBLEM TO BE SOLVED: To provide compounds for modulating protein kinase enzymatic activity.  <P>SOLUTION: The compounds for modulating protein kinase enzymatic activity for modulating cellular activity such as proliferation, differentiation, programmed cell death, migration and chemoinvasion are provided. More specifically, the compounds are quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in the cellular activity as the above. Compositions which contain these compounds and methods of using them to treat kinase-dependent diseases and conditions are also provided. Methods for producing the compounds and the compositions which contain these compounds are also provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system utilizes eye lid motion and/or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like. WO : s460 PCVSOI/ 260 -- ---
Dosage may be adjusted according to the condition and severity of symptoms. May be taken with or without water.

Adults and adolescents 12 years of age and older:1 to 2 tablets orally three or four times a day, thirty minutes to one hour before meals and at bedtime. Dosage may be increased to every four hours as needed. Do not exceed 12 tablets in 24 hours. 

Note:Geriatric patients may be more sensitive to the effects of the usual adult dose.
Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
The invention discloses blood pressure lowering footbath soup. The blood pressure lowering footbath soup consists of the following components by weight: 20-40g of mulberry leaf, 20-40g of mulberry twig, 20-40g of motherwort fruit and 5-15g of cinnamon. The materials are blended according to the prescription proportion, and 4,000ml of water is added into each dose to decoct soup. The conventional Chinese medicinal oral treatment method is broken through. The rare Chinese medicinal herbs of mulberry leaf, mulberry twig, motherwort fruit and cinnamon are selected to decoct the soup for footbath, and the foot sole and foot acupuncture reflective treatment effects are combined, so that the efficacy is doubled, and the effect is enhanced. The blood pressure lowering footbath soup is easy and convenient to prepare, is easy for the middle-aged patients to endure, and is free from toxic and side effects.
The invention relates to the technical field of herbal teas and especially relates to a ginger tea and a preparation method of ginger tea. The ginger tea comprises the following raw materials: white granulated sugar, sun-dried fresh ginger for a hundred days, five-finger fig roots, hoveniae semoveniae semen, Liubao tea, fructus momordicae, Chinese red dates, chrysanthemum flowers and licorices; and the raw materials are prepared into packaged ginger tea containing 10-20 grams of ginger tea in each bag. According to the preparation method, the sun-dried fresh ginger for a hundred days with the functions of warming the spleen and the stomach for dispelling cold, the Chinese red dates with the functions of nourishing the spleen and the stomach and replenishing Qi and the five-finger fig roots with the functions of invigorating the spleen and replenishing Qi are used as the main ingredients; and the food materials, including the hoveniae semoveniae semen with the function of dispelling damp-heat, the fructus momordicae with the functions of clearing away heat and relieving sore-throat and the chrysanthemum flowers with the function of dispelling wind-heat, are added into the main ingredients; thus, the dry natural of the sun-dried fresh ginger for a hundred days is relived and the product is thereby warm but not dry as a whole. The ginger tea does not cause heat easily after drinking and has very good effects of strengthening Yang, enhancing body resistance, dispelling moisture, regulating menstruation as well as warming up Qi and the blood. Moreover, licorice of sweet flavor and mild nature is matched in the ginger tea, so that the food materials are mediated to enhance effects of the ginger tea disclosed by the invention. The ginger tea is especially suitable for male of weak health and heavy moisture as well as female with painful menstruation and irregular menstruation to drink.
The measurement of attentional biases as a clinical evaluation tool in anxiety disorders is presented as a valuable instrument capable of evaluating changes in the automatic cognitive processes that are involved in their maintenance. However, the variability between the different methodologies used for its measurement has produced a lack of empirical consistency that supports the use of this tool with a clinical purpose. The appearance and implementation of eye tracking technology in experimental studies has made it possible to overcome this problem. Despite this, to our knowledge, there are still no studies that implement this technology in the clinical field as a tool for evaluating therapeutic effectiveness.

Specific phobia is the anxiety disorder with the highest prevalence and, specifically the animal subtype, is one of the most prevalent (3.8%), producing a significant interference and high comorbidity. Despite that in vivo exposure therapy is the treatment of choice for specific phobia, the high dropout rates and difficulties in its application pose major limitations for its therapeutic implementation. The emergence of technologies such as augmented reality (AR) has made it possible to overcome these barriers, offering new ways of applying exposure therapy. AR technology offers the capacity to interact with the stimulus in the real world, facilitating the therapeutic process and the generalization of its results. Some studies have tested the effectivity and efficacy of the AR technology in small animals exposure treatment revealing promising results. However, these studies used a version of AR that requires the use of a device placed on the participant's head (HDM-Head Mounted Display) which can cause dizziness and back pain in some participants and limits the therapist-patient communication. An improved version of the AR system based on projection helps to solve this problem, allowing a more natural interaction with the stimulus and the therapist and greater comfort. The preliminary efficacy of this system has been tested in a case study but, so far, there is no RCT evaluating the efficacy of this AR system. Therefore, in this work two objectives are pursued, firstly, to test and validate a projection-based AR system in the phobia of cockroaches treatment and, secondly, to evaluate the clinical potential of the eye-tracking technology as a specific measure to assess changes in cognitive processes.

The Randomized Clinical Trial (RCT) will be conducted following the Consolidated Standards of Reporting Trials (CONSORT: http://www.consort-statement.org) and the SPIRIT guidelines (Standard Protocol Items: Recommendations for Intervention Trials). Participants (N=96) will be randomized into three groups (after receiving a SP diagnosis - DSM-5): 1) Projection-based augmented reality therapy (P-ARET); 2) In vivo Exposure therapy (IVET); and 3) a waiting list control group (WL). Participants in the WL will be randomly assigned to one of the two treatment conditions after spending time on the waiting list (1 week) for ethical reasons. Outcome measures will be assessed at baseline, post-treatment and 1-, 6-, and 12-month follow-ups.
Hand dysfunction is a common observation after arteriovenous fistula (AVF) creation for hemodialysis access and has a variable clinical phenotype; however, the underlying mechanism responsible is unclear. Grip strength changes are a common metric used to assess AVF-associated hand disability but has previously been found to poorly correlate with the hemodynamic perturbations post-AVF placement implicating other tissue-level factors as drivers of hand outcomes. In this study, we sought to test if expression of a mitochondrial targeted catalase (mCAT) in skeletal muscle could reduce AVF-related limb dysfunction in mice with chronic kidney disease (CKD). Male and female C57BL/6J mice were fed an adenine-supplemented diet to induce CKD prior to placement of an AVF in the iliac vascular bundle. Adeno-associated virus was used to drive expression of either a green fluorescent protein (control) or mCAT using the muscle-specific human skeletal actin (HSA) gene promoter prior to AVF creation. As expected, the muscle-specific AAV-HSA-mCAT treatment did not impact blood urea nitrogen levels (P = 0.72), body weight (P = 0.84), or central hemodynamics including infrarenal aorta and inferior vena cava diameters (P > 0.18) or velocities (P > 0.38). Hindlimb perfusion recovery and muscle capillary densities were also unaffected by AAV-HSA-mCAT treatment. In contrast to muscle mass and myofiber size which were not different between groups, both absolute and specific muscle contractile forces measured via a nerve-mediated in-situ preparation were significantly greater in AAV-HSA-mCAT treated mice (P = 0.0012 and P = 0.0002). Morphological analysis of the post-synaptic neuromuscular junction uncovered greater acetylcholine receptor cluster areas (P = 0.0094) and lower fragmentation (P = 0.0010) in AAV-HSA-mCAT treated mice. Muscle mitochondrial oxidative phosphorylation was not different between groups, but AAV-HSA-mCAT treated mice had lower succinate-fueled mitochondrial hydrogen peroxide emission compared to AAV-HSA-GFP mice (P < 0.001). In summary, muscle-specific scavenging of mitochondrial hydrogen peroxide significantly improves neuromotor function in mice with CKD following AVF creation.
Guideline antibiotic therapy (at least 10 days iv antibiotic therapy and then per oral treatment to 6 weeks total by POET criteria). The antibiotic therapy is targeted according to microbiological analyses per microorganism.
Accounts of shared representations posit that the experience of pain and pain empathy rely on similar neural mechanisms. Experimental research employing novel analytical and methodological approaches has made significant advances in both the identification and targeted manipulation of such shared experiences and their neural underpinnings. This revealed that painful experiences can be shared on different representational levels, from pain-specific to domain-general features, such as negative affect and its regulation. In view of direct links between such representations and social behaviors such as prosocial behavior, conditions characterized by aberrant pain processing may come along with heavy impairments in the social domain, depending on the affected representational level. This has wide potential implications in light of the high prevalence of pain-related clinical conditions, their management, and the overuse of pain medication. In this review and opinion paper, we aim to chart the path toward a better understanding of the link between shared affect and prosocial behavior.
BACKGROUND: Cognitive dysfunction caused by infection frequently emerges as a complication in sepsis survivor patients. However, a comprehensive understanding of its pathogenesis remains elusive.
METHODS: In our in vivo experiments, an animal model of endotoxemia was employed, utilizing the Novel Object Recognition Test and Morris Water Maze Test to assess cognitive function. Various techniques, including immunofluorescent staining, Western blotting, blood‒brain barrier permeability assessment, Limulus Amebocyte Lysate (LAL) assay, and Proximity-ligation assay, were employed to identify brain pathological injury and neuroinflammation. To discern the role of Caspase-11 (Casp11) in hematopoietic or non-hematopoietic cells in endotoxemia-induced cognitive decline, bone marrow chimeras were generated through bone marrow transplantation (BMT) using wild-type (WT) and Casp11-deficient mice. In vitro studies involved treating BV2 cells with E. coli-derived outer membrane vesicles to mimic in vivo conditions.
RESULTS: Our findings indicate that the deficiency of Casp11-GSDMD signaling pathways reverses infection-induced cognitive dysfunction. Moreover, cognitive dysfunction can be ameliorated by blocking the IL-1 effect. Mechanistically, the absence of Casp11 signaling significantly mitigated blood‒brain barrier leakage, microglial activation, and synaptic damage in the hippocampal CA3 region, ultimately leading to improved cognitive function.
CONCLUSION: This study unveils the crucial contribution of Casp11 and GSDMD to cognitive impairments and spatial memory loss in a murine sepsis model. Targeting Casp11 signaling emerges as a promising strategy for preventing or treating cognitive dysfunction in patients with severe infections.
The present disclosure is related to a methodology for the construction of macrocycles inspired in the ruboxistaurin analog. These macrocycles contain in their structure: a triazole, a 1,3-disubstituted indole, one second aromatic system and a peptoid fragment. They were prepared by a sequence of reactions of multicomponent of Ugi-cycloaddition click. The atomic economy of the overall process is high, since only a water molecule is lost. Using this strategy, new Macrocycles with between 18 and 21 members were obtained. Furthermore, a bis-indole macrocycle was built. Finally, the cytotoxic activity of these macrocycles occurs in cancer cell lines.
Whether anti-inflammatory medications such as aspirin can lower the risk of frailty is an active area of investigation. In previous studies, we reported that regular aspirin use started in midlife was associated with a lower risk of frailty at older age. We therefore sought to further examine the relationship between inflammatory biomarkers, frailty and aspirin use in a pilot nested case-control study of 300 participants aged ≥60 years with available data to calculate a frailty index from the Physicians' Health Study, a completed randomized trial of aspirin that began in 1982. We selected 150 individuals who were frail (frailty index >0.2) and 150 who were not frail (frailty index <0.1). We then matched 29 low users of aspirin (≤60 days/year) 3:1 to 87 regular users of aspirin (>60 days/year). After matching on age, smoking status, history of diabetes and CVD, there was no significant association between aspirin use and level of frailty among those with elevated inflammatory biomarkers (all p>0.05). In this pilot study we did not find evidence of a mediation effect of CRP, TNFR-2 or IL-6 on the association between aspirin and frailty. Additional work is needed to elucidate the potential mechanistic pathways through which medications such as aspirin may be linked with frailty.
Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
This phase II trial will study the effectiveness of a combination regimen which includes Oncaspar (PEG-asparaginase), Doxil (PEG-liposomal doxorubicin), and Decadron (ODD) in terms of disease response against refractory lymphoid malignancies. Asparaginase is an enzyme that depletes asparagines, a key amino acid for survival and growth of malignant lymphocytes. Its depletion results in death of the neoplastic cell. Asparagine depletion has induced a significant improvement of clinical outcomes in acute lymphoblastic leukemia (ALL) and L-asparaginase has been a mainstay for more than 30 years in the treatment of ALL. Although this drug has been used primarily in ALL, promising results have been reported even in other non-ALL lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, refractory non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). One of the main goals of this trial is to measure the asparaginase level as a surrogate marker of asparagine depletion with Oncaspar, a PEG-enhanced version of E. coli L-asparaginase. The therapeutic value of the simple, non-pegylated form of L-asparaginase is limited by its short half-life and propensity to cause allergic reactions.
The medicament contains chloramphenicol adamantoate of formula: It is active against a wide variety of gram positive and negative bacteria, viruses and rickettsia. It is used in the treatment of infections, esp. influenza, and may also be used in veterinary medicine. Administration may be oral, rectal, parenteral or topical. Tablets and capsules pref. contain 350 mg., suppositories 300 mg., injections 5%, ointments and creams 2.5%, and eardrops 5% of active ingredient. Chloramphenicol adamtoate is prepared by reacting chloramphenicol with adamantoyl chloride in anhydrous pyridine.
The present disclosure includes a formulation of branched chain amino acids and arginine for treatment of diseases for which the pathological mechanism includes autophagy. The formulation includes defined ratios of the branched chain amino acids Isoleucine, Leucine, and Valine along with Arginine. These disease indications include congestive heart failure, myocardial infarction, and ischemia reperfusion injury. Diseases of other organs that involve autophagy are also disclosed. Additionally, methods of using the disclosed formulation to treat these disease indications are provided. The disclosure also describes a kit that includes a lyophilized form of the formulation, a solvent for reconstitution, and instructions directing reconstitution.
The invention relates to a composition capable of simultaneously reducing blood pressure, blood fat and blood sugar and application thereof, belonging to the technical field of health care products and medicines. The weight ratio of each component of the composition capable of reducing blood pressure, blood fat and blood sugar is as follows: total saponins of Notoginseng radix: mogrosides: theanine=1.5 to 2.5:0.5 to 1.5:1.5 to 2.5. The invention relates to application of the composition in preparing medicines for reducing blood pressure, blood fat and blood sugar. The invention relates to application of the composition in preparing health care products for reducing blood pressure, blood fat and blood sugar. The synergistic combination of the pseudo-ginseng total saponin, the mogroside and the theanine can effectively maintain blood sugar health, relieve theanine and relax tension emotion through lipid-lowering effect and nerve protection effect of the pseudo-ginseng total saponin and antioxidant effect of the mogroside, so as to achieve the effects of resisting anxiety and depression. The invention has rapid onset of action for reducing blood pressure, reducing blood sugar and reducing blood lipid, and lasting maintenance time.
A wound healing composition is provided that includes a tissue adhesive or epithelial tissue healing agent and metal-modified cerium oxide nanoparticles (mCNPs). The nCNPs have a predominant 3+ surface charge and are in a range of about 3-35 nanometers (nm) in size and mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive or epithelial tissue healing agent and the mCNPs. The metal (m) is a stable metallic metal with antimicrobial properties and non-ionizing. The mCNPs includes AgCNP2. A method is provided that uses the healing composition to treat a wound or epithelial tissue. The composition can be used to treat the skin or eye and/or subcutaneous tissue.